• Vascutek website

  • Terumo Group website

About Vascutek

VASCUTEK, a TERUMO Company

Vascutek, a Terumo Company

VASCUTEK,TERUMO Company is a world leader in the design and manufacture of products that address the needs of vascular and cardiovascular clinicians throughout the world.

For over 30 years, Vascutek has applied advanced and innovative technologies to develop a wide portfolio of products which include a AAA stent graft system and an extensive range of sealed woven and knitted polyester grafts for peripheral, abdominal and cardiothoracic surgery. Our range of products also feature ePTFE grafts..

Vascutek History

VASCUTEK, a TERUMO Company is a world leader in the design and manufacture of products that address the needs of vascular and cardiovascular clinicians throughout the world.

For 30 years, Vascutek has applied advanced and innovative technologies to develop a wide portfolio of products which include an extensive range of sealed woven and knitted polyester grafts for peripheral, abdominal and cardiothoracic surgery.

These technologies led to the development of Anaconda™, featuring BluGlide™, the new generation of AAA stent graft systems. It is the first repositionable device that also demonstrates exceptional flexibility.

Our range of products also feature ePTFE grafts.

1979 – Research and Development

Three groups worked together to develop a new vascular graft

Research and Development


1982 – Vascutek Ltd Founded

  • Vascutek develop unique knitting machines capable of knitting to 60 needles per inch
  • Triaxial™ and VP1200KTM grafts launched

Vascutek Ltd. founded


1983 – Development of our Gelatin Sealant Begins

Vascutek's unique modified gelatin sealant:

  • Removal in 14 days by simple hydrolysis
  • No enzymatic mechanism required
  • Antibiotic bonding option applies to all Vascutek sealed grafts
  • Now 37 publications to support this clinical application
  • CE Approval for the Rifampicin Bonding Process awarded in 2001

1983 Development of Gelatin Sealant Begins


1992 – First Gelweave™ Grafts Produced

  • GelweaveTM - a new design of zero porosity twill woven prosthesis

1992 Gelweave™ Graft Produced


1999 – First ePTFE Grafts Launched

  • Gelatin sealed Ultrathin ePTFE
  • Gelatin sealed Tapered ePTFE
  • ePTFE with unique ePTFE support
  • Unsealed Ultrathin ePTFE
SEALPTFEGelatin sealed Ultrathin ePTFE   Gelatin sealed Tapered ePTFEGelatin sealed Tapered ePTFE
ePTFE with unique ePTFE supportePTFE with unique ePTFE support   Unsealed Ultrathin ePTFEUnsealed Ultrathin ePTFE

2001 – Gelweave Valsalva™ Launched

Gelweave Valsalva™

  • A unique woven graft designed to closely match natural aortic root anatomy
  • Patent protected
  • FDA 510(K) received June 2002
  • Mimics stretch response of the sinuses of Valsalva
  • Reduces tension on coronary anastomoses
  • Minimises leaflet damage
  • Assists leaflet closure

Gelweave Valsalva™ Launched


2002 – Vascutek is Proud to Become Part of Terumo

 

VASCUTEK, a TERUMO Company


2005 – Rapidax™

Rapidax™

  • Access within 24 hours
  • Rapid haemostasis following needle withdrawal
  • Effectively no suture hole bleeding or "sweating"
  • Antibiotic Bonding Option

Rapidax™


2009 - Cobrahood™

ePTFE Vascular Prosthesis with Flared Outflow

  • Thin for excellent handling
  • Double layer wrap for added strength
  • Fully customisable hood

Cobrahood™


2009 – BluGlide™

  • Low friction hydrophilic coating significantly smoothes the passage of the delivery sheath through the arteries
  • Kink resistant sheath with graduated stiffness provides
    • Controlled delivery
    • Excellent manoeuvrability for varying patient anatomies
  • Highly radiopaque sheath tip marker for accurate deployment

BluGlide™


2010 – Gelweave Lupiae™ hybrid Debranching Graft

Gelweave Lupiae

  • Named after the Italian city where it was designed(Lupiae is the Roman name for the City of Lecce)
  • Indicated for hybrid surgical/endovasculardebranching procedures
  • Replacement of diseased, damaged aorta and associated side vessels
  • Safe, long and stable stent-graft landing zone
  • Patented radiopaque marker design facilitates accurate stent graft placement

2011 – The Launch of ONE-LOK™ Body

ONE-LOK Anaconda

  • The world’s FIRST repositionable stent graft
  • Patented magnet cannulation system
  • New ONE-LOK™ BODY – additional ring stents designed to maximise lumen diameter and blood flow
  • Common distal lumen docking zone diameter

2011 – The Development of Rapidax™ II

Rapidax II

  • Self sealing ePTFE dialysis graft
    • Rapid haemostasis following needle removal
    • Flexible suture zone designed to aid anastomosis formation
    • Straight & Loop configurations available
    • CE approved
    • Other markets pending

2011 – The Launch of Fenestrated Anaconda™

Fenestrated Anaconda

  • Unsupported body section maximises the available area for fenestrations
  • Repositionable facility enables accurate deployment
  • Patented magnet system can significantly reduce bifurcate body cannulation time

2012 – CE Approval for Thoraflex™ Hybrid

The world's first frozen elephant trunk device with aortic root plexus

Thoraflex Hybrid

Fully Gelatin Sealed Device

  • 1 Gelweave™ 4 branched Plexus™ graft
  • 2 Suture Collar - Aids anastomosis
  • 3 Ring stents
    • Individual ring stents of varying specific performance characteristics
  • Radiopaque Markers
    • Visibility of stented section
    • Aid for extension
  • 5 AnacondaTM fabric

Stent configuration based on AAA design
- Added stability
- Excellent anatomical conformability


2013 – Scottish Business Award for Innovation

20013 Scottish Bsuiness Award - category innovation

Vascutek is greatly honoured to have received the prestigious award Business Innovation of the Year for the second year running at the 2013 Scottish Business Awards.
The award was for the development of Fenestrated Anaconda™
These awards celebrate excellence in Scottish business and recognise the people and companies that are changing the face of Scotland with the goods, services and innovations that they provide.


2014 – Anaconda™ - Expanded Indication

Fenestrated Anaconda - CE Mark

Vascutek receives CE mark approval for Anaconda™ to be used to treat infrarenal abdominal aortic aneurysms in patients with proximal aortic neck angulations up to 90 degrees providing a clinical solution for patients with tortuous anatomy.

Ethics

Vascutek has always adopted a zero tolerance approach to unethical behaviour. We operate in an environment involving both ethical and legal responsibilities that extend not just to our employees, but to our customers, healthcare professionals, and other organisations with which we do business. The directors, officers, employees, consultants, representatives and agents of Vascutek are required to behave in an ethical manner at all times, and to comply with all laws, regulations, policies and procedures that affect their positions.

Download the Vascutek Ethics Statement here.

Download the Vascutek Modern Slavery Act 2015 Statement

Transparency

Publication des informations relatives aux liens d'intérêt 2012.

Publication des informations relatives aux liens d'intérêt 1er semestre 2013.pdf

Contact Vascutek

VASCUTEK, a TERUMO Company
Registered Office:
Newmains Avenue
Inchinnan
Renfrewshire PA4 9RR
Scotland UK

General Enquiries
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 00 44 141 812 5555
Fax: 00 44 141 812 7170


© 2011 Vascutek Ltd. a Terumo Company